What is the level of liabilities of SenzaGen this year?
SenzaGen has a debt balance of 29.57 M SEK this year.
SenzaGen Liabilities 2024
SenzaGen Liabilities
29.57 M SEK
SenzaGen Dividend yield
Ticker
SENZA.ST
ISIN
SE0010219626
WKN
A2DX79
In 2024, SenzaGen's total liabilities amounted to 29.57 M SEK, a -2.26% difference from the 30.25 M SEK total liabilities in the previous year.
SenzaGen Aktienanalyse
What does SenzaGen do?
SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing SenzaGen's Liabilities
SenzaGen's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SenzaGen's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing SenzaGen's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
SenzaGen's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in SenzaGen’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about SenzaGen Stock
What were the liabilities of SenzaGen compared to the previous year?
The liabilities of SenzaGen have increased by -2.26% dropped compared to the previous year.
What are the consequences of high debt for investors of SenzaGen?
High liabilities can pose a risk for investors of SenzaGen, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in SenzaGen?
Low liabilities mean that SenzaGen has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of SenzaGen affect the company?
An increase in liabilities of SenzaGen can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of SenzaGen affect the company?
A decrease in the liabilities of SenzaGen can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of SenzaGen?
Some factors that can influence the liabilities of SenzaGen include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of SenzaGen so important for investors?
The liabilities of SenzaGen are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can SenzaGen take to modify the liabilities?
To change its liabilities, SenzaGen can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does SenzaGen pay?
Over the past 12 months, SenzaGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SenzaGen is expected to pay a dividend of 0 SEK.
What is the dividend yield of SenzaGen?
The current dividend yield of SenzaGen is .
When does SenzaGen pay dividends?
SenzaGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of SenzaGen?
SenzaGen paid dividends every year for the past 0 years.
What is the dividend of SenzaGen?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is SenzaGen located?
SenzaGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von SenzaGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of SenzaGen from 5/25/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/25/2024.
When did SenzaGen pay the last dividend?
The last dividend was paid out on 5/25/2024.
What was the dividend of SenzaGen in the year 2023?
In the year 2023, SenzaGen distributed 0 SEK as dividends.
In which currency does SenzaGen pay out the dividend?
The dividends of SenzaGen are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von SenzaGen
Our stock analysis for SenzaGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SenzaGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
